Therapy Areas: Oncology
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK
1 October 2026 - Swedish pharmaceutical company Immedica Pharma AB, backed by investment firms KKR & Co. Inc. (NYSE: KKR) and Impilo, announced on Thursday that its partner, Spanish biopharmaceuti...
AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations
29 September 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) announced on Tuesday that it has agreed to invest USD2bn in newly issued equity in biopharmaceutical oncolo...
Fuse Oncology and Associated Medical Professionals of NY launch FuseRx proof of concept
29 September 2026 - Fuse Oncology Inc, a healthcare technology company focused on radiation oncology, announced on Monday that it has formed a strategic collaboration with Associated Medical Professio...
Leo Cancer Care invests in children's experience of radiotherapy, following world-first treatments
28 September 2026 - Radiotherapy technology company Leo Cancer Care on Sunday announced plans to further invest in the treatment experience for children undergoing radiation therapy.Following the worl...
Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC
28 September 2026 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Sunday an expansion of the global Phase 3 MarsLight-11 trial, which is evaluating IBI363 (Takeda ...
Akeso enrols first patient in global Phase III trial of cadonilimab vs nivolumab in first-line gastric cancer
28 September 2026 - Chinese pharmaceutical company Akeso Inc (HK:9926) announced on Sunday that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicentre Phase III head-t...